98%
921
2 minutes
20
Unlabelled: Genetically engineered mouse models (GEMM) have fundamentally changed how ovarian cancer etiology, early detection, and treatment are understood. MYC, an oncogene, is amongst the most amplified genes in high-grade serous ovarian cancer (HGSOC), but it has not previously been utilized to drive HGSOC GEMMs. We coupled Myc and dominant-negative mutant p53-R270H with a fallopian tube epithelium (FTE)-specific promoter Ovgp1 to generate a new GEMM of HGSOC. Female mice developed lethal cancer at an average of 14.5 months. Histopathologic examination of mice revealed HGSOC characteristics, including nuclear p53 and nuclear MYC in clusters of cells within the FTE and ovarian surface epithelium. Unexpectedly, nuclear p53 and MYC clustered cell expression was also identified in the uterine luminal epithelium, possibly from intraepithelial metastasis from the FTE. Extracted tumor cells exhibited strong loss of heterozygosity at the p53 locus, leaving the mutant allele. Copy-number alterations in these cancer cells were prevalent, disrupting a large fraction of genes. Transcriptome profiles most closely matched human HGSOC and serous endometrial cancer. Taken together, these results demonstrate that the Myc and Trp53-R270H transgenes were able to recapitulate many phenotypic hallmarks of HGSOC through the utilization of strictly human-mimetic genetic hallmarks of HGSOC. This new mouse model enables further exploration of ovarian cancer pathogenesis, particularly in the 50% of HGSOC which lack homology-directed repair mutations. Histologic and transcriptomic findings are consistent with the hypothesis that uterine serous cancer may originate from the FTE.
Significance: Mouse models using transgenes which generate spontaneous cancers are essential tools to examine the etiology of human diseases. Here, the first Myc-driven spontaneous model is described as a valid HGSOC model. Surprisingly, aspects of uterine serous carcinoma were also observed in this model.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425777 | PMC |
http://dx.doi.org/10.1158/2767-9764.CRC-24-0144 | DOI Listing |
J Pathol
September 2025
Department of Biomedical Sciences, Cornell University, Ithaca, NY, USA.
Serous endometrial carcinoma (SEC) is one of the most lethal types of uterine cancer, responsible for about 40% of all endometrial cancer-related deaths. Cell state dynamics during the early stages of SEC remain largely unknown, thereby hindering early detection and treatment of this disease. Here, we provide a comprehensive census of cell types and their states for normal, predysplastic, and dysplastic endometrium in a genetic mouse model of SEC.
View Article and Find Full Text PDFCancer Rep (Hoboken)
September 2025
ENT and Head and Neck Research Center and Department, the Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Objective: To present a case of metastatic endometrial carcinosarcoma (ECS) with a long-term complete response to chemotherapy using a paclitaxel and carboplatin regimen.
Case Report: A 47-year-old premenopausal woman was diagnosed with a large, advanced intrauterine tumor. She underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy.
Eur J Obstet Gynecol Reprod Biol
September 2025
Department of Biostatistics, Amrita Institute of Medical Sciences, Ponekkara Rd, Edappally, Kochi, Ernakulam 682041 Kerala, India.
Objective: This study compared the oncological outcomes of Pure Uterine Serous Carcinomas (p-USC) and p53-Abnormal Grade 3 Endometroid Endometrial Tumours (p53 Abn G3-EEC).
Methods: A retrospective study was conducted at Amrita Institute of Medical Sciences from February 1, 2015, to December 31, 2020, analysing patients diagnosed with P-USC and p53 Abn G3-EEC. The primary objective was to compare the 5-year Progression-Free Survival (PFS) between two groups.
J Forensic Sci
September 2025
Cook County Medical Examiner's Office, Chicago, Illinois, USA.
Pseudo-Meigs syndrome is a rare clinical entity characterized by the triad of ascites, pleural effusion, and a benign pelvic tumor other than an ovarian fibroma. Although typically considered benign and reversible following tumor removal, the syndrome can result in severe life-threatening compromise if unrecognized or untreated. Unlike the classical Meigs syndrome, which has occasionally been associated with fatal outcomes, no deaths related to pseudo-Meigs syndrome due to benign tumors have been previously reported.
View Article and Find Full Text PDFPharmaceutics
August 2025
OnCusp Therapeutics, 433 Broadway, New York, NY 10013, USA.
Cadherin-6 (CDH6), also known as K-cadherin, is a type II classic cadherin molecule that plays an important role in the embryonic development of the kidney but has very limited expression in adult tissues. It is overexpressed in several human malignancies, primarily in ovarian cancer, renal cell carcinoma, as well as, less frequently, cholangiocarcinoma, uterine serous carcinoma, glioma, lung, pancreatic and thyroid cancers. The characteristic of limited expression in normal tissues, high expression in tumor tissues, and rapid internalization upon antibody binding makes CDH6 a well-suited antibody-drug conjugate (ADC) target.
View Article and Find Full Text PDF